ERBB2 and breast cancer: Many CDKs inhibitors are currently being assessed in preclinical or in clinical trial investigations for cancer therapy; among them, a CDK4/6 selective inhibitor palbociclib has recently been approved for breast cancer treatment due to its selected and promising inhibitory effect on ER+/HER2- breast cancer [15–18].